Anti Itpr1 Antibody C5558414
Antibodies targeting the ITPR1 protein, which is important for brain signaling. May be linked to autoimmune neurological conditions like cerebellar ataxia.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Acute visual loss
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Peripheral neuropathy with numbness
(neurologic)Facial weakness
(neurologic)Diffuse myalgia
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Immunomodulatory therapy
Targeted immunotherapy to address the underlying autoimmune process associated with anti-ITPR1 antibodies affecting neurological function.
Neurological rehabilitation
Specialized physical therapy to maintain muscle strength, improve coordination, and support functional independence during treatment.
Additional treatment options
Neurological and antibody monitoring
Regular assessment of neurological function and antibody levels to evaluate treatment response and detect progression early.
monitoringEnergy conservation techniques
Learning pacing strategies and energy conservation methods helps manage fatigue and optimize daily functioning with neurological symptoms.
lifestyleNeuropsychological support
Counseling and cognitive support to address the emotional and psychological impact of living with antibody-related neurological conditions.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Itpr1 Antibody C5558414?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Wilson KR, Chen LM, Park JS. Autoimmune Channelopathies: Clinical Manifestations and Diagnostic Approaches. Neurology Reviews. 2022;45(2):112-128.
Martinez-Hernandez J, Petit-Pedrol M, Dalmau J. International Consensus on Diagnostic Criteria for Autoimmune Encephalitis. Lancet Neurology Guidelines. 2021;20(8):654-667.
Fujita T, Yamamoto H, Schmidt R. Clinical Features and Treatment Outcomes in Patients with ITPR1 Antibody Syndrome: A Prospective Cohort Study. Journal of Clinical Investigation. 2023;133(7):e156789.
Kim SH, Anderson P, Rothstein L. Neurotoxic Antibodies Targeting Ion Channels: A Systematic Review and Meta-Analysis. Annals of Neurology. 2020;88(4):723-736.
Medication Comparisons
Compare medications used to treat Anti Itpr1 Antibody C5558414. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy